June 13, 2026 — RNews

#diabetes — Saturday, June 13, 2026 (1 items)

hot top new

← prev day next day →

0

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. (linkinghub.elsevier.com)

Bajaj HS … Bartee A The Lancet 2026-06-13

#metabolism #clinical trial #diabetes #obesity #pharmacology